Lenvatinib's efficacy as a frontline targeted therapy for radioactive iodine-refractory thyroid carcinoma and advanced hepatocellular carcinoma owes to its inhibition of multiple tyrosine kinases. However, as a CYP3A4 substrate, lenvatinib bears susceptibility to pharmacokinetic modulation by co-administered agents. Schisantherin A (STA) and schisandrin A (SIA) - bioactive lignans abundant in the traditional Chinese medicinal Wuzhi Capsule - act as CYP3A4 inhibitors, engendering the potential for drug-drug interactions (DDIs) with lenvatinib. To explore potential DDIs between lenvatinib and STA/SIA, we developed a physiologically-based pharmacokinetic (PBPK) model for lenvatinib and used it to construct a DDI model for lenvatinib and STA/SIA. The model was validated with clinical trial data and used to predict changes in lenvatinib exposure with combined treatment. Following single-dose administration, the predicted area under the plasma concentration-time curve (AUC) and maximum plasma concentrations (Cmax) of lenvatinib increased 1.00- to 1.03-fold and 1.00- to 1.01-fold, respectively, in the presence of STA/SIA. Simulations of multiple-dose regimens revealed slightly greater interactions, with lenvatinib AUC0-t and Cmax increasing up to 1.09-fold and 1.02-fold, respectively. Our study developed the first PBPK and DDI models for lenvatinib as a victim drug. STA and SIA slightly increased lenvatinib exposure in simulations, providing clinically valuable information on the safety of concurrent use. Given the minimal pharmacokinetic changes, STA/SIA are unlikely to interact with lenvatinib through pharmacokinetic alterations synergistically but rather may enhance efficacy through inherent anti-cancer efficacy of STA/ SIA.
Background: Irinotecan (CPT-11) is a prodrug that is bioactivated to SN-38, which is primarily cleared via UGT1A1-mediated glucuronidation. Its complex metabolism, which also involves CYP3A-mediated oxidation, makes irinotecan highly susceptible to enzyme-mediated drug-drug interactions (DDIs). This study aimed to develop and qualify an adult whole-body physiologically based pharmacokinetic (PBPK) model of irinotecan and its metabolites (SN-38, SN-38G, and APC) to predict systemic pharmacokinetics and UGT1A1/CYP3A-mediated DDIs. Methods: An adult middle-out PBPK model was implemented in Simcyp®, integrating key pathways for carboxylesterase (CES) -mediated activation, UGT1A1/UGT1A9-driven glucuronidation, and CYP3A4/5-mediated oxidation. The model was calibrated using 175–300 mg/m 2 monotherapy data and was validated across a 33–750 mg/m 2 dose range, including drug-drug interactions with ketoconazole, sorafenib, and lopinavir/ritonavir. Results: Most observed irinotecan and SN-38 concentrations fell within the fifth–95th percentile prediction intervals, and dose–exposure slopes were close to unity. Across monotherapy evaluations, 54/56 (96.4%) comparisons of maximum concentration (C max ) and area under the concentration–time curve (AUC) met the 2-fold acceptance criterion. The model further captured the direction and magnitude of exposure changes across all inhibitor scenarios, with CPT-11 and SN-38 exposure ratios remaining within acceptable limits, although APC exposure was overpredicted in the ketoconazole scenario. Conclusion: The mechanistically informed and validated whole-body PBPK model reliably describes dose-dependent irinotecan and SN-38 pharmacokinetics and UGT1A1/CYP3A-mediated drug-drug interactions. This framework provides a clinically relevant tool for enzyme-mediated DDI risk assessment and for exploratory simulation of dose–exposure relationships under standard irinotecan regimens.